Jeffrey V Ravetch

List of Publications by Year in Descending Order

217 papers	41,787 citations	99 h-index	204 g-index
230 ext. papers	46,377 ext. citations	20.2 avg, IF	7.67 L-index

#	Paper	IF	Citations
217	A novel mouse strain optimized for chronic human antibody administration.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2123002119	11.5	
216	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. *Journal of Experimental Medicine*, **2021**, 218,	16.6	171
215	Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer. *Science Translational Medicine*, **2021**, 13,	17.5	11
214	Fc-engineered antibody therapeutics with improved efficacy against COVID-19 **2021**,		4
213	Site-Selective Chemoenzymatic Modification on the Core Fucose of an Antibody Enhances Its Fc Receptor Affinity and ADCC Activity. *Journal of the American Chemical Society*, **2021**, 143, 7828-7838	16.4	6
212	Antibody fucosylation predicts disease severity in secondary dengue infection. *Science*, **2021**, 372, 1102-1105	33.3	14
211	Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	13
210	Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function. *Cancer Research*, **2021**, 81, 956-967	10.1	23
209	Four keys to unlock IgG. *Journal of Experimental Medicine*, **2021**, 218,	16.6	5
208	One-Pot Conversion of Free Sialoglycans to Functionalized Glycan Oxazolines and Efficient Synthesis of Homogeneous Antibody-Drug Conjugates through Site-Specific Chemoenzymatic Glycan Remodeling. *Bioconjugate Chemistry*, **2021**, 32, 1888-1897	6.3	2
207	Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. *Nature*, **2021**, 599, 465-470	50.4	27
206	FcRn, but not FcRs, drives maternal-fetal transplacental transport of human IgG antibodies. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 12943-12951	11.5	25
205	A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 7981-7989	11.5	11
204	Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 32005-32016	11.5	28
203	Engineered ACE2 receptor traps potently neutralize SARS-CoV-2 **2020**,		9
202	Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection **2020**,		21
201	Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 28046-28055	11.5	110

200	Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. *Nature*, **2020**, 588, 485-490	50.4	40
199	The role of IgG Fc receptors in antibody-dependent enhancement. *Nature Reviews Immunology*, **2020**, 20, 633-643	36.5	140
198	Differential requirements for FcR engagement by protective antibodies against Ebola virus. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 20054-20062	11.5	29
197	Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways. *Journal of Clinical Investigation*, **2019**, 129, 3952-3962	15.9	21
196	Functional diversification of IgGs through Fc glycosylation. *Journal of Clinical Investigation*, **2019**, 129, 3492-3498	15.9	50
195	Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism. *Clinical Cancer Research*, **2019**, 25, 904-906	12.9	20
194	Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. *PLoS Pathogens*, **2018**, 14, e1006860	7.6	42
193	Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 12023-12027	11.5	45
192	SAR228810: an antibody for protofibrillar amyloid peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA). *Alzheimer's Research and Therapy*, **2018**, 10, 117	9	12
191	Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 11048-11053	11.5	32
190	IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E10915-E10924	11.5	60
189	Immunological responses to influenza vaccination: lessons for improving vaccine efficacy. *Current Opinion in Immunology*, **2018**, 53, 124-129	7.8	15
188	Anti-retroviral antibody FcR-mediated effector functions. *Immunological Reviews*, **2017**, 275, 285-295	11.3	40
187	IgG antibodies to dengue enhanced for FcRIIIA binding determine disease severity. *Science*, **2017**, 355, 395-398	33.3	170
186	Attenuated Vaccines for Augmented Immunity. *Cell Host and Microbe*, **2017**, 21, 314-315	23.4	3
185	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. *Immunity*, **2017**, 46, 577-586	32.3	225
184	Lysibodies are IgG Fc fusions with lysin binding domains targeting wall carbohydrates for effective phagocytosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 4781-4786	11.5	15
183	Diversification of IgG effector functions. *International Immunology*, **2017**, 29, 303-310	4.9	46

182	Signaling by Antibodies: Recent Progress. *Annual Review of Immunology*, **2017**, 35, 285-311	34.7	106
181	DC subset-specific induction of T cell responses upon antigen uptake via Fc receptors in vivo. *Journal of Experimental Medicine*, **2017**, 214, 1509-1528	16.6	33
180	Modulating IgG effector function by Fc glycan engineering. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 3485-3490	11.5	194
179	Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 10172-10177	11.5	29
178	Fc Receptor Function and the Design of Vaccination Strategies. *Immunity*, **2017**, 47, 224-233	32.3	99
177	Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs. *Journal of Molecular Biology*, **2017**, 429, 2528-2541	6.5	9
176	The Role and Function of Fc Receptors on Myeloid Cells **2017**, 405-427		7
175	Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. *Cell*, **2016**, 165, 1609-1620	56.2	103
174	Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcR Engagement. *Cancer Cell*, **2016**, 29, 820-831	24.3	91
173	Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. *Journal of Clinical Investigation*, **2016**, 126, 605-10	15.9	267
172	The Role and Function of Fc Receptors on Myeloid Cells. *Microbiology Spectrum*, **2016**, 4,	8.9	63
171	Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. *Cell Reports*, **2016**, 15, 2000-11	10.6	309
170	Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. *Science*, **2016**, 352, 1001-4	33.3	240
169	Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor Engagement. *Cancer Cell*, **2016**, 30, 369-371	24.3	4
168	Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions. *Cancer Immunology Research*, **2015**, 3, 704-13	12.5	84
167	Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. *Cell*, **2015**, 162, 160-9	56.2	116
166	Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. *Cell*, **2015**, 161, 1035-1045	56.2	170
165	Fc and Complement Receptors **2015**, 171-186		1

164	Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E2385-94	11.5	75
163	The role of Fc-FcR interactions in IgG-mediated microbial neutralization. *Journal of Experimental Medicine*, **2015**, 212, 1361-9	16.6	105
162	FcRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. *Cancer Cell*, **2015**, 28, 285-95	24.3	179
161	Fc receptor pathways during active and passive immunization. *Immunological Reviews*, **2015**, 268, 88-103	11.3	83
160	Immune complexes: not just an innocent bystander in chronic viral infection. *Immunity*, **2015**, 42, 213-215	32.3	14
159	Therapeutic Applications of Sialylated IVIG **2015**, 1509-1515		1
158	Abstract 1332: Interleukin-15 enhances rituximab-dependent cytotoxicity ex vivo and in vivo against a mouse lymphoma expressing human CD20 **2015**,		3
157	Broadly neutralizing hemagglutinin stalk-specific antibodies require FcR interactions for protection against influenza virus in vivo. *Nature Medicine*, **2014**, 20, 143-51	50.5	534
156	Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. *Cell*, **2014**, 158, 989-999	56.2	283
155	Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. *Cell*, **2014**, 158, 1243-1253	56.2	338
154	Type I and type II Fc receptors regulate innate and adaptive immunity. *Nature Immunology*, **2014**, 15, 707-16	19.1	335
153	Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. *Journal of Molecular Biology*, **2014**, 426, 3166-3179	6.5	107
152	Inhibitory Fc receptor is required for the maintenance of tolerance through distinct mechanisms. *Journal of Immunology*, **2014**, 192, 3021-8	5.3	47
151	Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. *Journal of Clinical Investigation*, **2014**, 124, 725-9	15.9	50
150	humanized mice to study FcR function. *Current Topics in Microbiology and Immunology*, **2014**, 382, 237-48	3.3	18
149	Therapeutic Applications of Sialylated IVIG **2014**, 1-7		
148	Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. *Journal of Virology*, **2013**, 87, 8535-44	6.6	20
147	Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. *Journal of Experimental Medicine*, **2013**, 210, 1695-710	16.6	948

146	Reply to Crispin et al.: Molecular model that accounts for the biological and physical properties of sialylated Fc. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E3547	11.5	7
145	General mechanism for modulating immunoglobulin effector function. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 9868-72	11.5	166
144	Acute inflammation primes myeloid effector cells for anti-inflammatory STAT6 signaling. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 13487-91	11.5	21
143	Antitumor activities of agonistic anti-TNFR antibodies require differential FcRIIB coengagement in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 19501-6	11.5	77
142	Novel roles for the IgG Fc glycan. *Annals of the New York Academy of Sciences*, **2012**, 1253, 170-80	6.5	137
141	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. *Nature*, **2012**, 492, 118-22	50.4	401
140	A mouse model for HIV-1 entry. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 15859-64	11.5	67
139	Mouse model recapitulating human Fc receptor structural and functional diversity. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 6181-6	11.5	192
138	Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fc receptor engagement. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 10966-71	11.5	79
137	Translating basic mechanisms of IgG effector activity into next generation cancer therapies. *Cancer Immunity*, **2012**, 12, 13		56
136	Inhibitory Fc receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. *Science*, **2011**, 333, 1030-4	33.3	243
135	Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. *Nature*, **2011**, 475, 110-3	50.4	465
134	FcRs in health and disease. *Current Topics in Microbiology and Immunology*, **2011**, 350, 105-25	3.3	117
133	Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant. *Journal of Immunology*, **2011**, 187, 3641-52	5.3	32
132	Antibody-mediated modulation of immune responses. *Immunological Reviews*, **2010**, 236, 265-75	11.3	217
131	Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. *Nature*, **2010**, 467, 591-5	50.4	332
130	In vivo veritas: the surprising roles of Fc receptors in immunity. *Nature Immunology*, **2010**, 11, 183-5	19.1	23
129	FcRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 19396-401	11.5	136

128	Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. *Journal of Experimental Medicine*, **2010**, 207, 2407-20	16.6	74
127	A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. *Journal of Clinical Immunology*, **2010**, 30 Suppl 1, S9-14	5.7	220
126	Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. *Journal of Cell Biology* , **2010**, 191, i7-i7	7.3	
125	Profile of Jeffrey Ravetch. Interview by Philip Downey. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 7689-91	11.5	
124	Fcgamma receptor-dependent expansion of a hyperactive monocyte subset in lupus-prone mice. *Arthritis and Rheumatism*, **2009**, 60, 2408-17		41
123	Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. *Nature*, **2009**, 458, 636-40	50.4	695
122	Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. *Nature Medicine*, **2009**, 15, 34-41	50.5	353
121	Fcgamma receptors as regulators of immune responses. *Nature Reviews Immunology*, **2008**, 8, 34-47	36.5	1961
120	Anti-inflammatory actions of intravenous immunoglobulin. *Annual Review of Immunology*, **2008**, 26, 513-33	34.7	430
119	Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. *Science*, **2008**, 320, 373-6	33.3	640
118	Identification of a receptor required for the anti-inflammatory activity of IVIG. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 19571-8	11.5	424
117	Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. *Journal of Immunology*, **2008**, 180, 1948-53	5.3	76
116	Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 20167-72	11.5	144
115	In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 15005-9	11.5	133
114	Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. *Journal of Immunology*, **2008**, 181, 6829-36	5.3	69
113	FcgammaRIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl-MpJ mice. *Journal of Immunology*, **2008**, 180, 5670-9	5.3	48
112	Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies. *Journal of Immunology*, **2008**, 181, 8745-52	5.3	37
111	Fc Receptors **2008**, 173-198		

110	Coordinate suppression of B cell lymphoma by PTEN and SHIP. *FASEB Journal*, **2008**, 22, 662.12	0.9	
109	Analyzing antibody-Fc-receptor interactions. *Methods in Molecular Biology*, **2008**, 415, 151-62	1.4	50
108	Fc-receptors as regulators of immunity. *Advances in Immunology*, **2007**, 96, 179-204	5.6	289
107	Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. *European Journal of Immunology*, **2007**, 37, 2973-82	6.1	91
106	Antibodies, Fc receptors and cancer. *Current Opinion in Immunology*, **2007**, 19, 239-45	7.8	197
105	Phagocytic cells. *Immunological Reviews*, **2007**, 219, 5-7	11.3	7
104	Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. *Journal of Experimental Medicine*, **2007**, 204, 1359-69	16.6	117
103	The antiinflammatory activity of IgG: the intravenous IgG paradox. *Journal of Experimental Medicine* , **2007**, 204, 11-5	16.6	223
102	Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 8433-7	11.5	201
101	Class A scavenger receptors regulate tolerance against apoptotic cells, and autoantibodies against these receptors are predictive of systemic lupus. *Journal of Experimental Medicine*, **2007**, 204, 2259-65	16.6	98
100	Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. *Trends in Immunology*, **2007**, 28, 74-9	14.4	91
99	Thymic stromal lymphopoietin transgenic mice develop cryoglobulinemia and hepatitis with similarities to human hepatitis C liver disease. *American Journal of Pathology*, **2007**, 170, 981-9	5.8	7
98	Rapid In Vivo Consumption and Ex Vivo Phagocytosis of WASP(-)Platelets.. *Blood*, **2007**, 110, 2103-2103	2.2	
97	Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. *Journal of Experimental Medicine*, **2006**, 203, 2157-64	16.6	198
96	Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. *Journal of Experimental Medicine*, **2006**, 203, 789-97	16.6	206
95	TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. *Journal of Experimental Medicine*, **2006**, 203, 553-61	16.6	280
94	Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 2758-63	11.5	160
93	Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. *Science*, **2006**, 313, 670-3	33.3	1331

92	Fcgamma receptors: old friends and new family members. *Immunity*, **2006**, 24, 19-28	32.3	862
91	Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. *Blood*, **2006**, 108, 705-10	2.2	30
90	New nomenclature for Fc receptor-like molecules. *Nature Immunology*, **2006**, 7, 431-2	19.1	52
89	Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdcd1-/- mice. *Journal of Experimental Medicine*, **2005**, 202, 1643-8	16.6	44
88	FcgammaRIV: a novel FcR with distinct IgG subclass specificity. *Immunity*, **2005**, 23, 41-51	32.3	521
87	Divergent immunoglobulin g subclass activity through selective Fc receptor binding. *Science*, **2005**, 310, 1510-2	33.3	788
86	Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. *Blood*, **2005**, 105, 3577-82	2.2	106
85	The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. *Nature Immunology*, **2005**, 6, 99-106	19.1	210
84	Restoration of tolerance in lupus by targeted inhibitory receptor expression. *Science*, **2005**, 307, 590-3	33.3	221
83	Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 2910-5	11.5	205
82	Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. *Journal of Clinical Investigation*, **2005**, 115, 2914-23	15.9	281
81	Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. *Cancer Research*, **2004**, 64, 5825-9	10.1	57
80	The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. *Journal of Experimental Medicine*, **2004**, 199, 1659-69	16.6	521
79	A critical role for Fc gamma RIIB in the induction of rheumatoid factors. *Journal of Immunology*, **2004**, 173, 4724-8	5.3	18
78	Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. *Blood*, **2004**, 103, 2397-400	2.2	79
77	Fc and Complement Receptors **2004**, 275-287		1
76	Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. *Blood*, **2003**, 102, 284-8	2.2	60
75	Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. *Annals of the New York Academy of Sciences*, **2003**, 987, 15-25	6.5	368

74	Deletion of the fcgamma receptor IIb in thymic stromal lymphopoietin transgenic mice aggravates membranoproliferative glomerulonephritis. *American Journal of Pathology*, **2003**, 163, 1127-36	5.8	36
73	Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. *Immunity*, **2003**, 18, 573-81	32.3	255
72	The naive B cell repertoire predisposes to antigen-induced systemic lupus erythematosus. *Journal of Immunology*, **2003**, 170, 4826-32	5.3	25
71	Macrophages control the retention and trafficking of B lymphocytes in the splenic marginal zone. *Journal of Experimental Medicine*, **2003**, 198, 333-40	16.6	190
70	Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. *Cancer Research*, **2003**, 63, 6453-7	10.1	79
69	Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. *Journal of Experimental Medicine*, **2002**, 195, 1167-74	16.6	223
68	Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. *Immunity*, **2002**, 16, 861-8	32.3	55
67	Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. *Journal of Experimental Medicine*, **2002**, 195, 1653-9	16.6	316
66	A full complement of receptors in immune complex diseases. *Journal of Clinical Investigation*, **2002**, 110, 1759-61	15.9	48
65	IgG Fc receptors. *Annual Review of Immunology*, **2001**, 19, 275-90	34.7	1389
64	T cell studies in a peptide-induced model of systemic lupus erythematosus. *Journal of Immunology*, **2001**, 166, 1667-74	5.3	36
63	Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. *Journal of Experimental Medicine*, **2001**, 194, 769-79	16.6	1501
62	Current Understanding of Possible Mechanisms of Action and Resistance of Rituximab. *Clinical Lymphoma and Myeloma*, **2001**, 2, 145-147		
61	Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. *Science*, **2001**, 291, 484-6	33.3	871
60	Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. *Nature Medicine*, **2000**, 6, 443-6	50.5	2222
59	Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. *Nature Immunology*, **2000**, 1, 31-6	19.1	438
58	Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. *Journal of Experimental Medicine*, **2000**, 191, 899-906	16.6	180
57	Fc gamma receptor IIB on follicular dendritic cells regulates the B cell recall response. *Journal of Immunology*, **2000**, 164, 6268-75	5.3	145

56	Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. *Immunity*, **2000**, 13, 277-85	32.3	643
55	Inhibitory pathways triggered by ITIM-containing receptors. *Advances in Immunology*, **1999**, 72, 149-77	5.6	175
54	High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia. *Journal of Experimental Medicine*, **1999**, 190, 1689-96	16.6	76
53	Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG. *Journal of Experimental Medicine*, **1999**, 189, 1573-9	16.6	156
52	B cell antigen receptor engagement inhibits stromal cell-derived factor (SDF)-1alpha chemotaxis and promotes protein kinase C (PKC)-induced internalization of CXCR4. *Journal of Experimental Medicine*, **1999**, 189, 1461-6	16.6	88
51	SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis. *Immunity*, **1999**, 10, 753-60	32.3	188
50	Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. *Journal of Experimental Medicine*, **1999**, 189, 179-85	16.6	338
49	Biochemical nature and cellular distribution of the paired immunoglobulin-like receptors, PIR-A and PIR-B. *Journal of Experimental Medicine*, **1999**, 189, 309-18	16.6	128
48	Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. *Journal of Experimental Medicine*, **1999**, 189, 187-94	16.6	287
47	Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. *Kidney International*, **1998**, 54, 1166-74	9.9	128
46	Divergent roles for Fc receptors and complement in vivo. *Annual Review of Immunology*, **1998**, 16, 421-32	34.7	315
45	SHIP modulates immune receptor responses by regulating membrane association of Btk. *Immunity*, **1998**, 8, 509-16	32.3	342
44	Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. *Science*, **1998**, 279, 1052-4	33.3	531
43	T cell development in mice lacking all T cell receptor zeta family members (Zeta, eta, and FcepsilonRIgamma). *Journal of Experimental Medicine*, **1998**, 187, 1093-101	16.6	43
42	Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclasses. *Journal of Experimental Medicine*, **1998**, 187, 641-8	16.6	73
41	CD4+ T cell-mediated granulomatous pathology in schistosomiasis is downregulated by a B cell-dependent mechanism requiring Fc receptor signaling. *Journal of Experimental Medicine*, **1998**, 187, 619-29	16.6	159
40	Insights into the mechanisms of antibody-affinity maturation and the generation of the memory B-cell compartment using genetically altered mice. *Autoimmunity*, **1998**, 6, 305-16		
39	Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling. *Cell*, **1997**, 90, 293-301	56.2	451

38	Fc receptors. *Current Opinion in Immunology*, **1997**, 9, 121-5	7.8	211
37	Synergy between an antibody and CD8+ cells in eliminating an established tumor. *European Journal of Immunology*, **1997**, 27, 374-82	6.1	31
36	A dominant role for mast cell Fc receptors in the Arthus reaction. *Immunity*, **1996**, 5, 387-90	32.3	150
35	T lymphocyte development in the absence of Fc epsilon receptor I gamma subunit: analysis of thymic-dependent and independent alpha beta and gamma delta pathways. *European Journal of Immunology*, **1996**, 26, 1935-43	6.1	18
34	Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. *Nature*, **1996**, 379, 346-9	50.4	730
33	Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. *Nature*, **1996**, 383, 263-6	50.4	670
32	Molecular determinants of the myristoyl-electrostatic switch of MARCKS. *Journal of Biological Chemistry*, **1996**, 271, 18797-802	5.4	95
31	Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. *Journal of Experimental Medicine*, **1996**, 184, 2385-92	16.6	188
30	Cytotoxic antibodies trigger inflammation through Fc receptors. *Immunity*, **1995**, 3, 21-6	32.3	212
29	A YAC contig map of Plasmodium falciparum chromosome 4: characterization of a DNA amplification between two recently separated isolates. *Genomics*, **1995**, 26, 192-8	4.3	24
28	Differential contribution of the FcR gamma chain to the surface expression of the T cell receptor among T cells localized in epithelia: analysis of FcR gamma-deficient mice. *European Journal of Immunology*, **1995**, 25, 2107-10	6.1	42
27	Transcriptional and nucleosomal characterization of a subtelomeric gene cluster flanking a site of chromosomal rearrangements in Plasmodium falciparum. *Nucleic Acids Research*, **1994**, 22, 4176-82	20.1	24
26	Chromatin structure determines the sites of chromosome breakages in Plasmodium falciparum. *Nucleic Acids Research*, **1994**, 22, 3099-103	20.1	38
25	A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. *Nature*, **1994**, 368, 70-3	50.4	436
24	FcR gamma chain deletion results in pleiotrophic effector cell defects. *Cell*, **1994**, 76, 519-29	56.2	817
23	Fc receptors: rubor redux. *Cell*, **1994**, 78, 553-60	56.2	330
22	Fc receptor signaling. *Advances in Experimental Medicine and Biology*, **1994**, 365, 185-95	3.6	9
21	Transcriptional differences in polymorphic and conserved domains of a complete cloned P. falciparum chromosome. *Nature*, **1993**, 361, 654-7	50.4	64

20	A sequence element associated with the Plasmodium falciparum KAHRP gene is the site of developmentally regulated protein-DNA interactions. *Nucleic Acids Research*, **1992**, 20, 3051-6	20.1	56
19	Characterization of yeast artificial chromosomes from Plasmodium falciparum: construction of a stable, representative library and cloning of telomeric DNA fragments. *Genomics*, **1992**, 14, 332-9	4.3	45
18	Fc gamma RIII (CD16) on human macrophages is a functional product of the Fc gamma RIII-2 gene. *European Journal of Immunology*, **1991**, 21, 425-9	6.1	43
17	Functional consequences of lipid-mediated protein-membrane interactions. *Biochemical Pharmacology*, **1991**, 42, 1-11	6	21
16	A single amino acid in the glycosyl phosphatidylinositol attachment domain determines the membrane topology of Fc gamma RIII. *Nature*, **1989**, 342, 805-7	50.4	165
15	Chromosomal polymorphisms and gene expression in Plasmodium falciparum. *Experimental Parasitology*, **1989**, 68, 121-5	2.1	26
14	Large deletions result from breakage and healing of P. falciparum chromosomes. *Cell*, **1988**, 55, 869-74	56.2	172
13	Knob-associated histidine-rich protein gene. *Nature*, **1987**, 326, 550-550	50.4	
12	A chromosomal rearrangement in a P. falciparum histidine-rich protein gene is associated with the knobless phenotype. *Nature*, **1986**, 322, 474-7	50.4	159
11	A tandemly repeated sequence determines the binding domain for an erythrocyte receptor binding protein of P. falciparum. *Cell*, **1986**, 44, 689-96	56.2	100
10	Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. *Nature*, **1985**, 315, 672-6	50.4	837
9	Molecular Genetic Strategies for the Development of Anti-Malarial Vaccines. *Bio/technology*, **1985**, 3, 729-740		21
8	Primary structure and genomic organization of the histidine-rich protein of the malaria parasite Plasmodium lophurae. *Nature*, **1984**, 312, 616-20	50.4	84
7	Inversion in the H-2 complex of t-haplotypes in mice. *Nature*, **1983**, 306, 380-3	50.4	76
6	Structure of the human immunoglobulin mu locus: characterization of embryonic and rearranged J and D genes. *Cell*, **1981**, 27, 583-91	56.2	844
5	DNA sequence analysis of the defective interfering particles of bacteriophage f1. *Journal of Molecular Biology*, **1979**, 128, 305-18	6.5	15
4	Mapping of bacteriophage f1 ribosome binding sites to their cognate genes. *Virology*, **1977**, 81, 341-51	3.6	17
3	Isolation and characterisation of the phiX174 ribosome binding sites. *Nature*, **1977**, 265, 698-702	50.4	12

2	Intact 3Send of 16S rRNA is not required for specific mRNA binding. *Nature*, **1976**, 262, 150-3	50.4	15
1	Thermodynamic and kinetic properties of short RNA helices: the oligomer sequence AnGCUn. *Nucleic Acids Research*, **1974**, 1, 109-27	20.1	35